Our commitments

In 2012, we developed forward-looking commitments across the four areas of our responsible business approach.

They aim to address unmet global health needs and are aligned with our strategic priorities and our values.

Each year we report on our progress against these commitments and here we provide a summary for those that relate to Our behaviour.

Promoting values in sales and marketing practices

Continue to drive a values-based approach to sales and marketing practices across the world, with the interests of consumers and patients at its core.

Progress: On track

Announced changes to our global sales and marketing practices to further ensure patient interests come first, and introduced a new performance management system focused on values.

Rigorous patient and consumer safety

Continue to ensure the interests and safety of patients and consumers are of paramount importance in the way we design and undertake our clinical trials, our product quality assurance and our monitoring and reporting of adverse events in ongoing product usage.

Progress: Progressing well

Strengthened resources to enhance our pharmocovigilance operating model, expanded dedicated product quality teams and maintained our robust policies and governance framework on patient safety.

Minimising animal testing

Rigorously challenge the need for animal studies and work to minimise the impact on animal welfare, by investing in the development of alternative studies and sharing animal-based data.

Progress: On track

Reduced number of animals used in our research by 10% in 2013.

Promoting Human Rights

Address the UN Guiding Principles on Human Rights and Business across our own operations and our supplier relationships.

Progress: On track

Conducted a human rights impact assessment and prioritised seven areas for further analysis, and updated our human rights statement accordingly.

Transparency in clinical trial data

Be as transparent as possible with our clinical trial data, including publishing clinical study reports (without patient-level data) for all outcome trials of medicines conducted by GSK and, within an appropriate process, making available to researchers access to anonymised patient level data to further scientific enquiry.

Progress: Progressing well

Launched online system enabling researchers to request access to the detailed anonymised patient-level data from our clinical trials and became first pharmaceutical company to publish clinical study reports.

Ensuring ethical stakeholder interactions

Demonstrate that all GSK interactions with patient advocacy groups and political stakeholders are conducted appropriately, ethically and transparently.

Progress: On track

Embedded new criteria to ensure public policy groups we work with are aligned with our values and agreed relevant Standard Operating Procedures.